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Abstract. Three series of polycyclic compounds possessing either primary sulfonamide or carboxylic 
acid moieties as zinc-binding groups were investigated as inhibitors of four physiologically relevant 
CA isoforms, the cytosolic hCA I and II, as well as the transmembrane hCA IX and XII. Most of the 
new sulfonamides reported here showed excellent inhibitory effects against isoforms hCA II, IX and 
XII, but no highly isoform-selective inhibition profiles. On the other hand, the carboxylates 
selectively inhibited hCA IX (KIs ranging between 40.8 and 92.7 nM) without inhibiting significantly 
the other isoforms. Sulfonamides/carboxylates incorporating polycyclic ring systems such as 
benzothiopyranopyrimidine, pyridothiopyranopyrimidine or benzothiopyranopyrazole may be 
considered as interesting candidates for exploring the design of isoform-selective CAIs with various 
pharmacologic applications. 
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1. Introduction 
 
 Sulfonamides possessing the general formula RSO2NH2 constitute the historically most 
important class of carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAIs).1-8 They are in clinical use 
for more than 70 years as diuretics, antiglaucoma, antiepileptic, and antiobesity agents,1-7 and, more 
recently, they have shown applications as antitumor/antimetastatic agents or diagnostic tools, with at 
least one sulfonamide in Phase I clinical trials for the treatment of advanced, metastatic solid tumors.8 
 Recently,1 we have disclosed a new class of sulfonamides 1a-e, featuring the classical 
benzenesulfonamide moiety for binding to the catalytically crucial zinc ion forming the enzyme active 
site. The head part of these molecules is connected to a pyrazole moiety, further annealed with a bulky 
heterocyclic ring, benzothiopyrano[4,3-c]pyrazole (comp 1a-c) and pyridothiopyrano[4,3-c]pyrazole 
(comp 1d-e), (Chart 1) in order to explore both alternative chemotypes and the possibility to further 
enhance the isoform selectivity observed with celecoxib (CLX) and valdecoxib (VLX) as CAIs.2-8 
Actually, compounds 1a-e may be regarded as geometrically constrained analogues of the two 
reference leads CLX and VLX.  
 The most interesting feature of this new class of sulfonamides was their capability to 
predominantly exert strong inhibition of only hCA I and II, as well as of the mycobacterial β-class 
enzymes (Rv1284, Rv3273, and Rv3588c), conversely their inhibitory activity against hCA III, IV, 
VA, VB, VI, VII, IX, XII, XIII, and XIV was at least 2 orders of magnitude lower. The combination 
of X-ray crystal structure of the hCA II-compound 1e adduct, and homology modeling allowed to 
explain this peculiar inhibition profile, which was also quite different from those of the reference 
coxibs, CLX and VLX. Thus, the benzenesulfonamides 1a-e constitute a highly interesting class of 
compounds which, inhibiting only a restricted number of physiologically relevant CA isoforms 
among the 12 catalytically active human enzymes, should lead to fewer side effects. In addition, the 
good inhibition profile of some of the new derivatives (1d-e) against mycobacterial CAs is also to be 
considered as relevant because these enzymes are less inhibited by other classes of sulfonamides. 
 As further development of this project, in the present work we aim to study three novel series 
of compounds in search for selective CAIs. In the first class (compounds 2a-d, Chart 1), we decided 
to move the benzensulfonamido function from position 1 to position 2 of the pyrazole system of 
benzothiopyrano[4,3-c]pyrazole (2a,b) and pyridothiopyrano[4,3-c]pyrazole (2c,d), to assess 
whether this change of position could lead to selective compounds for some CA isoforms. 
Substituents at 7-position (R) were chosen considering the groups that most contributed to the activity 
of the above described compounds 1a-e.1 
 
 
 
Chart 1: Sulfonamide CAIs of types 1-4 discussed in the paper. 
 
 Then, with the aim to identify novel chemotypes to further expand the chemical diversity in 
CAIs, we searched among our in-house database of heteropolycyclic scaffold-based derivatives 
synthesized in our laboratories.9-13 Benzothiopyranopyrimidines (3a-c) and 
pyridothiopyranopyrimidines (3d-e) reported by us earlier,11,13 attracted our attention due to their 
structural similarity to the pyrazoles of types 1 and 2. Thus, in this work, we considered compounds 
3a-e, featuring a carboxylic group. Actually, it was reported that carboxylates14-16 share with 
dithiocarbamates17-19 the CA inhibition mechanism of sulfonamides and their bioisosteres 
(sulfamates, sulfamides),20,21 representing one of the main class of pharmacologically relevant 
CAIs.20-23  
 Finally, the benzothiopyranopyrimido and the pyridothiopyranopyrimido scaffolds were 
further investigated, by the design of compounds 4a-e (Chart1), that bear a benzensulfonamide 
moiety, typical of the classical CAIs, in the 2-position of the tricyclic system and spaced by an NH 
linker. 
 
 
 
2. Results and Discussion 
 
2.1. Chemistry. 
The preparation of the 2-(p-sulfonamidophenyl)substituted-pyrazole derivatives 2a-d was performed 
following the synthetic route described in Scheme 1. The starting key intermediates 7-substituted-3-
hydroxymethylenebenzothiopyranones 5a-b9 or 3-hydroxymethylenepyridothiopyranones 5c-d10,11 
were converted into the corresponding p-toluensulfonates 6a-d. In these intermediates the reactive 
methine functionality was protected as previously reported by us.12 The subsequent condensation of 
6a-d with 4-sulfonamidophenylhydrazine hydrochloride, in anhydrous dimethylformamide at room 
temperature, involved, as a first step, only the carbonyl functionalization at the 4-position, affording 
the intermediate arylhydrazones.12 These latter easily cyclized in situ by heating the reaction mixture 
at 100 °C, to afford the desired 2-substituted derivatives 2a-d. The compounds were purified by flash 
chromatography and characterized by analytical and spectral data (see Experimental protocols for 
details) which were in accordance with analogues compounds of previous works.1, 9, 12  
 
 
Scheme 1. Preparation of sulfonamides 2a-d. 
 
The synthetic pathway leading to the target 2-(p-benzensulfonamido)benzothiopyranopyrimidines 
4a-c and 2-(p-benzensulfonamido)pyridothiopyranopyrimidines 4d-e takes advantage of the use as 
“synthetic tool” of the 7-substituted benzothiopyrano or pyridothiopyrano moiety, which 
demonstrated to be versatile intermediates in many synthetic procedures.13 The 1,3-bielectrophile 
reactivity of the 7-substituted-3-dimethylaminomethylene derivatives 7a-e 13,24-26 in the reaction with 
 
 
the 4-guanidinobenzenesulfonamide 827 in butanol at reflux, in the presence of sodium hydroxide,28 
allowed to easily obtain the desired 2-benzensulfonamidophenyl substituted pyrimidines 4a-e, as 
reported in Scheme 2. The 4-guanidinobenzenesulfonamide 8 was obtained in good yields by reaction 
of a 50% cyanamide solution in water and a solution of sulfanilamide in concentrated HCl. The 
mixture was heated at 100 °C for 20 minutes, as already described.27 
The purity of the target compounds was assessed by TLC analysis and by physicochemical properties, 
analytical and 1H NMR and 13C NMR spectral data, which were in agreement with the proposed 
structures and with other previously reported results. (Experimental protocols for details).  
 
 
Scheme 2. Synthesis of sulfonamides 4a-e. 
 
2.2. CA inhibition 
The compounds 2a-d, 3a-e and 4a-e reported here were investigated for their enzyme inhibitory 
capacity against four physiologically relevant CA isoforms, the human (h) hCA I, II, IX and XII 
(Table 1). Acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulfonamide) was used as standard drug 
in the assay.28 
 
 
 
Table 1. Inhibition of isoforms hCA I, II, IX and XII with sulfonamides 2a-d, by a stopped-flow CO2 
hydrase assay.28 Acetazolamide (AAZ) used as standard inhibitor. 
 
 
      2a-d 
 
 
 
 
 
 
 
* Mean from 3 different assays. Errors in the range of ±10 of the reported values. 
 
The data listed in Table 1 show that benezenesulfonamides 2a-d, bearing the bulky condensed 
tricyclic tail, do inhibit significantly all four investigated isoforms, with inhibition constants in the 
range of 22.5 - 68.4 nM against hCA I, 7.1 - 8.5 nM against hCA II, 6.1 - 7.7 nM against hCA IX and 
38.1 - 68.6 nM against hCA XII, respectively. The structure-activity relationship (SAR) against all 
four isoforms is quite flat, since the substituent R and the X moiety show to little influence the 
inhibitory activity. The other salient feature is that the isoform-selectivity, observed with compounds 
1 reported earlier, is lost for the sulfonamides 2. This may be presumably attributed to the capacity 
of the quite bulky scaffold present in the derivatives investigated here, to interact favorably with the 
active sites of the four CA isoforms. 
Thus, as the shift of the benzensulfonamide moiety from position 1 to position 2 of the pyrazole 
system (compounds 2a-d) led to less isoform selective compounds, we decided to continue the study 
in this area by changing the starting pyrazole with a pyrimidine ring fused on the benzothiopyrano or 
N X R KI (nM)* 
hCA I hCA II hCA IX hCA XII 
2a CH Cl 41.5 8.5 6.1 68.6 
2b CH OCH3 68.4 7.4 7.4 38.1 
2c N H 22.5 7.1 6.3 66.7 
2d N CH3 37.1 7.6 7.7 62.5 
AAZ - - 250 12 25 5.6 
 
 
pyridothiopyrano moiety, thus obtaining compounds 3 and 4, whose inhibition data are reported in 
Tables 2 and 3. 
 
Table 2. Inhibition of isoforms hCA I, II, IX and XII with carboxylic acids 3a-e, by a stopped-flow 
CO2 hydrase assay.
28 Acetazolamide (AAZ) used as standard inhibitor 
 
3a-e 
N X R R1 R2 KI (nM)* 
hCA I hCA II hCA IX hCA XII 
3a CH OCH3 COOH CH3 510 5390 40.8 8390 
3b  CH  OCH3 COOH H  871 4220 54.1 5975 
3c  CH OCH3  (CH2)2CH(NH2)COOH  H  >50000  >50000  335 9030 
3d  N H  COOH CH3 440  638  67.8  7170  
3e N  CH3 COOH CH3 370 7450 92.7 6185 
AAZ - - -  250 12 25 5.6 
* Mean from 3 different assays. Errors in the range of ±10 of the reported values. 
 
Data of Table 2 show that the carboxylic acids 3 (except the one with the longer aliphatic chain, 3c) 
possess a more interesting inhibition profile against the four CA isoforms compared to sulfonamides 
2. Indeed, compounds 3a,b,d and e behaved as hCA IX-selective inhibitors (KIs in that range of 40.8 
- 92.7 nM) with much lower affinity for hCA I, II and XII, for which KIs in the range of 370 - 9030 
nM were measured (Table 2). The lysine derivative 3c did not significantly inhibited hCA I, II and 
XII, being a weak hCA IX inhibitor too (KI of 335 nM). 
 
 
 
 
 
 
Table 3. Inhibition of isoforms hCA I, II, IX and XII with sulfonamides 4a-e, by a stopped-flow CO2 
hydrase assay.28 Acetazolamide (AAZ) used as standard inhibitor. 
 
4a-e 
N X R KI (nM)* 
hCA I hCA II hCA IX hCA XII 
4a CH  H 80.5 96.0 7.0 75.1 
4b CH  OCH3 66.9 63.2 22.5 48.9 
4c CH  Cl 84.0 218 8.7 15.5 
4d N H 68.3 9.4 27.6 17.8 
4e N CH3 68.9 8.0 8.1 34.4 
AAZ - - 250 12 25 5.6 
* Mean from 3 different assays. Errors in the range of ±10 of the reported values. 
 
Data of Table 3 show that all CA isoforms investigated here were inhibited by sulfonamides 4a-e. 
The slow cytosolic isoform hCA I was inhibited moderately, with KIs ranging between 66.9 and 84.0 
nM. Again the SAR is rather flat for this isoform, proving that the nature of the X and R fragments 
of the molecule do not significantly influence the biological activity. This is however not the case for 
the inhibition of the physiologically dominant isoform hCA II, for which a more diversified inhibitory 
behavior has been evidenced for these sulfonamides. Indeed, 4d and 4e were low nanomolar highly 
effective hCA II inhibitors (KIs ranging between 8.0 and 9.4 nM), being thus more effective than the 
standard drug AAZ, whereas 4a-c showed a reduced efficacy, with KIs ranging between 63.2 and 218 
nM. Thus, the best substitution pattern is that incorporating pyridine and not benzene in the terminal 
ring of the polycyclic system. The presence of H or Me as R moieties was not highly influential on 
the hCA II inhibition profile of these compounds. 
The transmebrane isoform hCA IX, a validated antitumor target,8 was also effectively inhibited by 
sulfonamides 4, which showed KIs ranging between 7.0 and 27.6 nM (Table 3). In this case both 
benzene- and pyridine in the third ring of the polycyclic system led to effective inhibitors (e.g., 
 
 
compare 4a and 4e which show very similar KI values). The methoxy moiety (in 4b) led to an almost 
three-fold loss of inhibitory efficacy (compared to 4a), whereas chlorine (in 4c) was better tolerated, 
with the last compound having a similar activity as 4a. The presence of the methyl moiety in 4e was 
this time beneficial for the hCA IX inhibitory effects, with this compound being 3-times more potent 
compared to 4d, which has a hydrogen in place of the methyl group (Table 3). 
The second transmembrane isoform investigated here, hCA XII, was also effectively inhibited by 
these sulfonamides, which had KIs ranging between 15.5 and 75.1 nM. The best inhibitors were the 
chlorine derivative in the benzene series (4c) and the unsubstituted derivative (R = H, 4d) in the 
pyridine serie with KIs of 15.5 nM and  17.8 nM, respectively (Table 3). 
 
3. Conclusions 
Primary sulfonamides 2 and 4 or carboxylic acids 3 incorporating polycyclic ring systems such as 
benzothiopyranopyrimidine, pyridothiopyranopyrimidine or dihydrobenzothiopyranopyrazole were 
investigated as inhibitors of four physiologically relevant CA isoforms, the cytosolic hCA I and II, as 
well as the transmembrane hCA IX and XII. An excellent inhibitory activity against isoforms hCA 
II, IX and XII was shown by most of the new sulfonamides 2 and 4, although with a low selectivity 
among the various isoforms. The carboxylates 3, on the other hand, acted as hCA IX-selective 
inhibitors (KIs in that range of 40.8 - 92.7 nM), with much lower affinity for hCA I, II and XII. Thus, 
sulfonamide or carboxylic acid moieties as zinc-binding groups connected to a pyrazole or a 
pyrimidine moiety annealed with a bulky heterocyclic ring may be considered as interesting 
candidates for exploring the design of novel isoform-selective CAIs with various pharmacologic 
applications. 
 
4. Experimental Section 
4.1. Chemistry 
General. The uncorrected melting points were determined using a Reichert Köfler hot-stage 
apparatus. NMR spectra were obtained on a Bruker AVANCE 400 (1H, 400 MHz, 13C, 100 MHz) in 
DMSO-d6  or CDCl3 (internal standard tetramethylsilane). The coupling constants are given in Hertz. 
Magnesium sulphate was used as the drying agent. Evaporations were made in vacuo (rotating 
evaporator). Analytical TLC have been carried out on Merck 0.2 mm precoated silica gel aluminium 
sheets (60 F-254). Silica gel 60 (230-400 mesh) was used for column chromatography. Purity of the 
 
 
target inhibitors 2a-d, 3a-e, and 4a-e was determined, using a Shimadzu LC-20AD SP liquid 
chromatograph equipped with a DDA Detector at 196 nm (column C18 (250 mm x 4.6 mm, 5 µm, 
Shim-pack)). The mobile phase, delivered at isocratic flow, consisted of acetonitrile (40–60%) and 
water (60–40%) and a flow rate of 1.0 mL/min. All the compounds showed percent purity values of 
>95%. Reagents, starting materials, and solvents were purchased from commercial suppliers and used 
as received. According to the methods described previously the following substrates were obtained:7-
Methoxy-2,3-dihydro-3-hydroxymethylene-1-benzothiopyran-4(4H)-one 5a and 7-chloro-2,3-
dihydro-3-hydroxymethylene-1-benzothiopyran-4(4H)-one 5b9, 2,3-dihydro-3-
hydroxymethylenethiopyrano[2,3-b]-pyridin-4(4H)-one 5c10, 7-Methyl-2,3-dihydro-3-
hydroxymethylenethiopyrano[2,3-b]-pyridin-4(4H)-one 5d 11, 3-[(p-Methylphenyl)sulfonyl] 
oxymethylen-2,3-dihydrobenzothiopyran-4(4H)-one 6a9, 3-[(p-Methylphenyl)sulhonyl] 
oxymethylen-2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one 6c and 7-Methyl-3-[(p-
Methylphenyl)sulhonyl]oxymethylen-2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one 6d12, 3-
Dimethylaminomethylen-2,3-dihydrobenzo[3',2':5,6]thiopyran-4(4H)-one 7a,26 7-Methoxy-3-
dimethylaminomethylen-2,3-dihydrobenzo[3',2':5,6]thiopyran-4(4H)-one 7b13, 7-Chloro-3-
dimethylaminomethylen-2,3-dihydrobenzo[3',2':5,6]thiopyran-4(4H)-one 7c26, 2,3-Dihydro-3-
dimethylaminomethylenethiopyrano[2,3-b]pyridin-4(4H)-one 7d and 7-Methyl-2,3-Dihydro-3-
dimethylaminomethylenethiopyrano[2,3-b]pyridin-4(4H)-one 7e11, N-(4-Aminosulfonylphenyl) 
guanidine carbonate 8.27 Compounds 3a-e were already described by us; in particular compounds 3a-
c were described in ref.13 and compounds 3d-e in ref.11 
3-[(p-Methylphenyl)sulfonyl]chloromethylen-2,3-dihydrobenzothiopyran-4(4H)-one 6b 
p-Toluensulphonylchloride (0.801 g, 4.8 mmoles) was added to a solution of 5b (0.903 g, 2.4mmoles) 
in 8 mL of anhydrous tetrahydrofurane in the presence of potassium carbonate (1.161 g, 9.6 mmoles). 
The reaction mixture, under nitrogen atmosphere, was stirred at room temperature for 15 hours then 
refluxed for 3 hours. After cooling, the suspension was concentrated under reduced pressure, and the 
residue obtained was treated with water and then extracted with chloroform. The organic layers were 
dried and evaporated to give crude product 6b which was purified by flash chromatography on a silica 
gel column (60/0.040-0.063 mm) using petroleum ether 40-60°C/ethyl acetate 8/2 as the eluting 
system. Yield 22%, mp 80-82 °C. 1H NMR (400 MHz, CDCl3): ppm) 2.50 (s, 3H, CH3), 3.83 (s, 
2H, CH2), 7.20 (dd, 1H, Ar-H, Jmax = 8.4 Hz, Jmin = 2.0 Hz), 7.29 (dd, 1H, Ar-H, J = 2 Hz), 7.43 
(d, 2H, Ar-H), 7.67-7.68 (m, 1H, CH), 7.87-7.89 (m, 2H, Ar-H), 8.04 (d, 1H, ArH, J = 8.4 Hz).  
General Procedure for the synthesis of 7-Substituted-2-(p-sulfonamidophenyl)-1,4-
dihydrobenzothiopyrano[4,3-c]pyrazoles 2a-b and 7-Substituted-2-(p-sulfonamidophenyl)-1,4-
dihydro-pyrido[3′,2′:5,6]-thiopyrano[4,3-c]pyrazoles 2c-d 
 
 
4-Hydrazinobenzenesulfonamide hydrochloride (0.300g, 1.3 mmoles) in 9 ml of N,N-
dimethylformamide was added dropwise to a solution of the opportune derivative 6a-d (2.00 mmoles) 
in 6 mL of the same solvent. The reaction mixture was stirred at room temperature for 15 hours, then 
refluxed for 2 hours. After cooling, the suspension was poured into a saturated aqueous potassium 
carbonate solution and extracted with chloroform. The organic layers were dried and evaporated 
under reduced pressure to give desired crude pyrazoles 2a-d which were purified by flash 
chromatography on a silica gel column (60/0.040-0.063 mm) using petroleum ether 40-60 °C/ethyl 
acetate 4/6 as the eluting system. 
7-Methoxy-2-(p-sulfamidophenyl)-1,4-diidrobenzothiopyranopyrazole 2a 
Yield 35%, mp 230-232 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 3.74 (s, 3H, OCH3), 3.99 (s, 
2H, CH2-S), 6.67 (d, 1H, Ar-H, Jmax = 8.8 Hz; Jmin = 2.4 Hz), 6.76-6.74 (m, 1H, Ar-H), 7.09 (d, 
1H, Ar-H, J = 2.4 Hz.), 7.53 (s, 2H, NH2 exch.), 77.61 (d, 2H, Ar-H J = 8.8 Hz), 7.71 (s, 1H, Ar-H), 
7.95 (d, 2H, Ar-H, J = 8.8 Hz). 13C NMR (100 MHz, DMSO-d6): (ppm) 23.24, 55.87, 112.53, 
114.30, 117.06, 118.54, 126.23, 126.30, 127.52, 135.63, 137.87, 137.90, 143.16, 143.98, 159.33. 
7-Cloro-2-(p-sulfamidophenyl)-1,4-diidrobenzothiopyranopyrazole 2b 
Yield 51%, mp: 210-212 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 4.04 (s, 2H, CH2), 6.81 (d, 
1H, Ar-H, J = 8.8 Hz), 7.16 (dd, 1H, Ar-H, Jmax = 8.4, Jmin = 2.0 Hz), 7.53 (bs, 2H, NH2 exch.), 
7.60-7.64 (m, 3H, Ar-H), 7.78 (s, 1H, Ar-H), 7.94-7.96 (m, 2H, Ar-H). 13C NMR (100 MHz, DMSO-
d6): (ppm) 23.12, 118.81, 124.48, 126.21, 126.34, 126.40, 127.63, 128.61, 133.12, 136.29, 137.06, 
138.04, 142.81, 144.20. 
2-(p-Sulfamidophenyl)-1,4-diidropiridothiopyranopyrazole 2c 
Yield 30%, mp 213-215 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 4.19 (s, 2H, CH2), 7.05-7.07 
(m, 2H, Ar-H), 7.54 (bs, 2H, NH2 exch.), 7.61-7.63 (m, 2H, Ar-H), 7.78 (s, 1H, Ar-H), 7.94-7.96 (m, 
2H, Ar-H), 8.29-8.30 (m, 1H, Ar-H). 13C NMR (100 MHz, DMSO-d6): (ppm) 22.90, 118.13, 
120.77, 121.69, 126.35, 127.64, 131.52, 136.75, 138.20, 142.64, 144.35, 148.76, 157.44. 
7-Methyl-2-(p-sulfamidophenyl)-1,4-diidropiridothiopyranopyrazole 2d 
Yield 25%, mp 235-238 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 2.38 (s, 3H, CH3), 4.15 (s, 2H, 
CH2S), 6.90 (d, 1H, Ar-H, J = 8.0 Hz), 6.95 (d, 1H, Ar-H, J = 8.8 Hz), 7.52 (s, 2H, NH2 exch.), 7.59-
7.61 (m, 2H, Ar-H), 7.75 (s, 1H, Ar-H), 7.93-7.95 (m, 2H, Ar-H). 13C NMR (100 MHz, DMSO-d6): 
(ppm) 22.99, 24.03, 117.41, 118.97, 120.15, 126.28, 127.61, 131.80, 137.00, 138.13, 142.70, 
144.29, 156.73, 157.74. 
General procedure for the synthesis of 4-((8-substituted-5H-thiochroman[4,3-d]pyrimidin-2-
yl)amino)benzenesulfonamides 4a-c and 4-((8-substituted-5H-pyrido[3',2':5,6]thiopyrano[4,3-
d]pyrimidin-2-yl)amino)benzenesulfonamides 4d-e 
 
 
N-(4-Aminosulfonylphenyl)guanidine carbonate 8 (0.332 g, 1.2 mmol ) and NaOH (0.096 g, 2.4 
mmoles) were added to a solution of the appropriate 3-dimethylaminomethylen-2,3-
dihydrobenzo[3',2':5,6]thiopyran-4(4H)-one 7a-c or 2,3-Dihydro-3-dimethylamino-
methylenethiopyrano[2,3-b]pyridin-4(4H)-one 7d-e (1.2 mmoles) in 10 mL of n-BuOH. The solution 
was heated at 120 °C for 4 hours and, after cooling, the precipitate obtained was collected by filtration 
to give crude pyrimidines which were purified by flash chromatography on a silica gel column 
(60/0.040-0.063 mm) using ethyl acetate/Hexane = 5/5 as the eluting system. 
4-((5H-thiochroman[4,3-d]pyrimidin-2-yl)amino)benzenesulfonamide 4a 
Yield 44%, mp 275-278 °C. 1H-NMR (400 MHz, DMSO-d6): (ppm) 4.07 (s, 2H, CH2), 7.20 (s, 2H, 
NH2 exch.), 7.41-7.47 (m, 3H, Ar-H), 7.76-7.78 (m, 2H, Ar-H), 7.97-8.00 (m, 2H, Ar-H), 8.32-8.34 
(m, 1H, Ar-H), 8.56 (s, 1H, Ar-H), 10.15 (bs, 1H, NH, exch). 13C NMR (100 MHz, DMSO-d6): 
(ppm) 26.42, 116.66, 118.21, 126.83, 127.10, 127.67, 128.43, 131.83, 132.40, 136.58, 137.12, 
144.16, 157.00, 158.41, 159.43. 
4-((8-Methoxy-5H-thiochroman[4,3-d]pyrimidin-2-yl)amino)benzenesulfonamide 4b 
Yield 31%, mp 228-230 °C. 1H-NMR (400 MHz, DMSO-d6): (ppm) 3.85 (s, 3H, -OCH3), 4.05 (s, 
2H, CH2), 6.98-7.01 (m, 2H, Ar-H), 7.19 (bs, 2H, NH2 exch.), 7.76 (d, 2H, Ar-H, J = 8.8 Hz), 7.98 
(d, 2H, Ar-H, J = 9.2 Hz), 8.27 (d, 1H, Ar-H, J = 8.8 Hz), 8.48 (s, 1H, Ar-H), 10.07 (bs, 1H, NH 
exch.). 13C NMR (100 MHz, DMSO-d6): (ppm) 26.64 56.09, 112.68, 113.63, 115.47, 118.10, 
125.11, 127.08, 129.36, 136.40, 139.0, 144.26, 156.50, 158.42, 159.33, 161.93. 
4-((8-Chloro-5H-thiochroman[4,3-d]pyrimidin-2-yl)amino)benzenesulfonamide 4c 
Yield 45%, mp 268- 270 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 4.10 (s, 2H, CH2), 7.21 (s, 2H, 
NH2 exch.), 7.47-7.50 (dd, 1H, Ar-H, Jmax = 8.6, Jmin = 2.4 Hz), 7.60 (d, 1H, Ar H,  J = 2.4 Hz), 
7.77 (d, 2H, Ar-H, J = 8.8 Hz), 7.97 (d, 2H, Ar-H, J = 8.8 Hz), 8.30 (d, 1H, Ar-H, J = 8.8 Hz), 8.57(s, 
1H, Ar-H), 10.19 (s, 1H, NH exch.). 13C NMR (100 MHz, DMSO-d6): (ppm) 26.40, 116.27, 118.25, 
126.94, 127.12, 127.68, 129.20, 131.22, 136.41, 136.67, 139.46, 144.05, 157.24, 157.59, 159.43. 
4-((5H-Pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidin-2-yl)amino)benzenesulfonamide 4d 
Yield 45%, mp 283-285 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 4.23 (s, 2H, CH2), 7.19 (s, 2H, 
NH2 exch.), 7.41-7.44 (m, 1H, Ar H), 7.78 (d, 2H, Ar H, J = 8.8 Hz), 7.97 (d, 2H, Ar H, J = 8.8 Hz), 
8.52-8.54 (m, 1H), 8.57-8.59 (m, 1H), 8.60 (s, 1H, Ar H), 10.18 (bs, 1H, NH exch.). 13C NMR (100 
MHz, DMSO-d6): (ppm) 26.31, 115.62, 118.36, 121.84, 127.14, 128.66, 134.75, 136.76, 143.95, 
151.90, 157.57, 157.75, 159.41, 160.13. 
4-((8-Methyl-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidin-2-yl)amino)benzenesulfonamide 
4 e 
 
 
Yield 45%, mp 283-285 °C. 1H NMR (400 MHz, DMSO-d6): (ppm) 4.20 (s, 2H, CH2), 7.21 (s, 2H, 
NH2 exch.), 7.27 (d, 2H, Ar-H, J = 8.8 Hz), 7.96 (d, 2H, Ar-H, J = 8.8 Hz), 8.46 (1, 2H, Ar-H, J = 8.0 
Hz), 8.56 (s, 1H, Ar-H), 10.17 (s, 1H, NH exch.). 13C NMR (400 MHz, DMSO-d6): (ppm) 24.42, 
26.36, 115.20, 118.27, 121.38, 125.97, 127.13, 135.01, 136.66, 144.01, 157.31, 157.98, 159.36, 
159.46, 161.28. 
 
 
4.2. CA inhibition. An Applied Photophysics stopped-flow instrument has been used for assaying the 
CA catalysed CO2 hydration activity.
28 Phenol red (at a concentration of 0.2 mM) has been used as 
indicator, working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 
20 mM Na2SO4 (for maintaining constant the ionic strength), following the initial rates of the CA-
catalyzed CO2 hydration reaction for a period of 10-100 s. The CO2 concentrations ranged from 1.7 to 
17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at 
least six traces of the initial 5-10% of the reaction have been used for determining the initial velocity. 
The uncatalyzed rates were determined in the same manner and subtracted from the total observed 
rates. Stock solutions of inhibitor (0.1 mM) were prepared in distilled-deionized water and dilutions 
up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were 
preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation 
of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using 
PRISM 3 and the Cheng-Prusoff equation, as reported earlier,29-31 and represent the mean from at least 
three different determinations. All CA isofoms were recombinant ones obtained in-house as reported 
earlier.29-31 
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